Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.53 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 8/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | ALPL | P05186 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6454404 | 0.79 | KDR (0.39) | TRPV1NPC1ALPLRAB9ASMN1; SMN2 | |
| SCHEMBL6449942 | 0.78 | MEN1 (0.40) | SCN5ASCN9ATRPV1NPC1ALPL | |
| SCHEMBL6453884 | 0.78 | TRPV1 (0.44) | TRPV1NOTUMNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6454148 | 0.78 | SMN1; SMN2 (0.53) | SCN5ASCN9ATRPV1NPC1RAB9A | |
| SCHEMBL6454218 | 0.77 | IDO1 (0.42) | TRPV1SMN1; SMN2HPGDALOX15 | |
| SCHEMBL6450021 | 0.77 | ADORA2A (0.53) | TRPV1NPC1ALPLRAB9ASMN1; SMN2 | |
| SCHEMBL6453583 | 0.77 | JAK2 (0.58) | JAK2TRPV1NPC1ALPLRAB9A | |
| SCHEMBL6448731 | 0.75 | NR1H2 (0.56) | TRPV1NR1H2NR1H3 | |
| SCHEMBL6451042 | 0.74 | GRK6 (0.40) | TRPV1KDR | |
| SCHEMBL5959907 | 0.73 | SMN1; SMN2 (0.69) | JAK2NOTUMNPC1ALPLRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| WO-2004110351-A2 | HETEROCYCLIC COMPOUNDS FOR TREATING HEPATITIS C VIRUS | ANADYS PHARMACEUTICALS, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | HAVCR2, HCCS, LIPC | JAK2 524/4885SCN5A 4270/4885SCN9A 4771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.